open-label extension of the hope-2 trial

Conditions: Duchenne Muscular Dystrophy

Summary: this phase 2, multi-center, open-label extension trial will provide deramiocel (cap-1002) to subjects that were enrolled in the hope-2 trial and completed 12 months of follow-up. the trial will explore the safety and efficacy of twenty intravenous administrations of deramiocel, each separated by three months. subjects will undergo a targeted screening during a 30-day screening period, eligible subjects will then undergo baseline safety and efficacy assessments on day 1 prior to their first infusion of deramiocel. subjects will complete trial assessments at screening; day 1; months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, and 60. safety and efficacy assessments will be conducted prior to deramiocel administration at the day 1, months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, and 57 trial visits, unless otherwise indicated. all deramiocel infusions will be conducted in an outpatient setting at the investigative site on day 1 and months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, and 57. subjects will be observed in the outpatient setting for at least two hours post infusion and then discharged the same day, if medically cleared by the site investigator.

this phase 2, multi-center, open-label extension trial will provide deramiocel (cap-1002) to subjects that were enrolled in the hope-2 trial and completed 12 months of follow-up. the trial will explore the safety and efficacy of twenty intravenous administrations of deramiocel, each separated by three months. subjects will undergo a targeted screening during a 30-day screening period to determine eligibility based on protocol inclusion and exclusion criteria. eligible subjects will undergo baseline safety and efficacy assessments on day 1 prior to their first infusion of deramiocel. administration of deramiocel (day 1) should occur within a maximum of 30 days following confirmation of eligibility. subjects will complete trial assessments at screening; day 1; months 3, 6, 9, 12 (± 14 days, each), 15, 18, 21, 24, 27, 30, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, and 60 (± 21 days, each). safety and efficacy assessments will be conducted prior to deramiocel administration at the day 1, months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, and 57 trial visits, unless otherwise indicated. all deramiocel infusions will be conducted in an outpatient setting at the investigative site on day 1 and months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, and 57. prior to each deramiocel administration, medications will be administered to the subject as determined by the investigator based on the pre-treatment guidelines as outlined in the protocol and/or institutional protocols to minimize the risk of potential severe allergic reactions such as anaphylaxis. subjects will be observed in the outpatient setting for at least two hours post infusion and then discharged the same day if medically cleared by the site investigator. if clinically indicated, an unscheduled in-person visit will be performed at the investigative site with targeted assessments based on presentation of signs and symptoms following any infusion.

Eligibility criteria:
inclusion criteria: 1. documented enrollment in the hope-2 trial and completion of trial follow-up through month 12 2. willing and able to provide informed consent to participate in the trial if ≥ 18 years of age, and assent with parental or guardian informed consent if \< 18 years of age 3. adequate venous access for intravenous deramiocel (cap-1002) infusions in the judgement of the investigator 4. assessed by the investigator as willing and able to comply with the requirements of the trial exclusion criteria: 1. planned or likely major surgery in the next 12 months after planned first infusion 2. risk of near-term respiratory decompensation in the judgment of the investigator, or the need for initiation of non-invasive ventilator support as defined by serum bicarbonate ≥ 29 mmol/l 3. history of non dmd-related chronic respiratory disease including, but not limited to, asthma, bronchitis, and tuberculosis 4. acute respiratory illness within 60 days prior to first infusion 5. known hypersensitivity to dimethyl sulfoxide (dmso) or bovine products 6. treatment with an investigational product ≤ 6 months prior to first infusion 7. history, or current use, of drugs or alcohol that could impair ability to comply with participation in the trial 8. inability to comply with the investigational plan and follow-up visit schedule for any reason, in the judgment of the investigator

Keywords: dmd, muscular dystrophy, duchenne